Document:

Exhibit
10.1

 

April
22, 2021

 

Tariq
Arshad, MD

1545
Bayberry View Lane

San
Ramon, CA 94582

drtariqarshad@outlook.com

(908)
240-7602

 

Full-Time
Employment Offer

 

Dear
Dr. Arshad,

 

We
are pleased to offer you the position of Senior Vice President & Chief Medical Officer with Qualigen Therapeutics, Inc. (the “Company”).
This position and its responsibilities will utilize your talents, education and experience to meet the Company’s needs in this
important area. (You would also serve in the same capacity, without additional compensation, for the Company’s wholly-owned subsidiary
Qualigen, Inc.) We are confident that you will find the position to be a challenging and enjoyable career opportunity. The position is
being offered to you on the following terms:

 

	 	1.	Position:	Senior
    Vice President & Chief Medical Officer 
	 	 	 	 
	 	2.
    	Reports
    to:	Amy
    Broidrick, Executive Vice President/Chief Strategy Officer
	 	 	 	 
	 	3.
    	Start
    Date:	We
    mutually anticipate your employment start date will be May 17, 2021 (the actual start date, the “Start Date”).
	 	 	 	 
	 	4.	Compensation:	Your
    initial annualized base salary will be at the rate of $400,000 per year, payable bi-weekly according to the Company’s payroll
    practices. The base salary will be reviewed annually as part of the Company’s normal salary review process. You will be eligible
    for annual performance-based cash bonuses as may be awarded by the Board of Directors and its Compensation Committee based upon your
    performance and the achievement of objectives established for the year by the Board of Directors and its Compensation Committee,
    with the annual target bonus being expressed as a percentage, established each year by the Board of Directors and its Compensation
    Committee, of your base salary. For 2021, your bonus target will be 40% of your annualized base salary.
	 	 	 	 
	 	 	 	In
    addition, you shall be entitled to reimbursement for reasonable travel and other business expenses that adhere to the Company’s
    travel and expense documentation and other policies. 
	 	 	 	 
	 	5.
    	Signing
    Bonus:	A
    cash signing bonus of $25,000 will be paid on the first regular bi-weekly pay date after the Start Date.
	 	 	 	 
	 	6.	Insurance
    Benefits:	As
    of July 1, 2021, you and your eligible dependents will be eligible to participate in the Company’s group medical, dental, vision,
    disability and life insurance plans. The Company reserves the right to (on a nondiscriminatory basis) terminate, replace or change
    these plans and all other benefit plans and programs.
	 	 	 	 
	 	7.	Paid
    Vacation:	Vacation
    accrues at the rate of 6.15 hours per bi-weekly pay period (4 weeks per year) according to the Company’s standard policies,
    subject to any and all accrual caps imposed by such policies (as they may be revised from time to time).
	 	 	 	 
	 	8.	401(k)
    Plan:	After
    completing three months of employment, you are entitled to participate in the Company’s 401(k) retirement savings plan, subject
    to IRS contribution limits. The Company presently matches 50% of employee contributions (subject to IRS matching limits), provided
    that no further matching is provided in a year after the employee has contributed 6% of total actual annual salary/bonus.

 

    	 

    	 

    

 

	 	9.
    	Stock
    Options:	The
    Company’s management will recommend to the Board of Directors and its Compensation Committee that the Company grant to you,
    on the Start Date, stock options under the Company’s 2020 Stock Incentive Plan to purchase 100,000 shares of the Company’s
    common stock, at an exercise price per share equal to the fair market value on the grant date, with the scheduled expiration date
    of the stock options to be the 10th anniversary of the Start Date. The stock options would be documented on and subject to the terms
    and conditions of the Company’s standard form of Stock Option Agreement, and would be subject to equal annual vesting on each
    of the first three anniversaries of the Start Date (in each case vesting would depend on your being in the service of the Company
    on the vesting date).
	 	 	 	 
	 	 	 	In
    addition, upon satisfactory completion of the first 90 days of employment, the Company’s management will recommend to the Board
    of Directors and its Compensation Committee that the Company grant to you stock options under the Company’s 2020 Stock Incentive
    Plan to purchase an additional 300,000 shares of the Company’s common stock, at an exercise price per share equal to the fair
    market value on the grant date, with the scheduled expiration date of the additional stock options to be the 10th anniversary of
    the Start Date. The additional stock options would be documented on and subject to the terms and conditions of the Company’s
    standard form of Stock Option Agreement, and would be subject to equal annual vesting on each of the first three anniversaries of
    the Start Date (in each case vesting would depend on your being in the service of the Company on the vesting date). It is understood
    that the Company’s ability to grant any such additional options is subject to approval, at the Company’s July 15, 2021
    Annual Meeting of Stockholders, of the proposal to expand the 2020 Stock Incentive Plan.
	 	 	 	 
	 	10.	Other
    Benefits:	In
    addition to the benefits listed above, you also will be eligible for paid sick-leave as and to the extent outlined in the Employee
    Handbook and be entitled to participate in other benefit programs adopted by the Company from time to time for its employees generally.
	 	 	 	 
	 	11.	Severance:	You
    shall not be entitled to any severance or separation benefits except under the following circumstances: 
	 	 	 	 
	 	 	 	If
    (after the first 90 days of your employment, which is your probationary period) your employment is terminated without Cause or you
    resign for Good Reason, then if and only if within 30 days after such termination without Cause or resignation with Good Reason you
    execute and deliver a customary and satisfactory general release of all claims (with a nondisparagement provision) in favor of the
    Company and its related persons, you will be entitled to 180 days of salary continuation plus (should you timely elect to continue
    coverage pursuant to COBRA) the cost of COBRA coverage continuation for such 180 day period. 

 

    	 

    	 

    

 

	 	 	 	“Cause”
    means any of the following: (i) a material breach by you of any of the trade secret/proprietary information, confidential information
    or intellectual property ownership sections of your Confidential Information and Invention Assignment Agreement; (ii) a material
    breach by you of any other provision of the Employment Agreement, if such material breach (if susceptible to cure) has continued
    uncured for a period of at least 15 days following delivery by the Company to you of written notice of such material breach; (iii)
    fraud, dishonesty or other breach of trust whereby you obtain personal gain or benefit at the expense of or to the detriment of the
    Company or any of the Company’s subsidiaries or affiliates; (iv) a conviction of or plea of nolo contendere or similar plea
    by you of any felony; (v) a conviction of or plea of nolo contendere or similar plea by you of any other crime involving theft, misappropriation
    of property, dishonesty or moral turpitude; (vi) a willful and material violation of applicable law by you in connection with the
    performance of your employment duties; (vii) chronic or repeated substance abuse, or any other use of alcohol, drugs or illegal substances
    in such a manner as to interfere with the performance of your material employment duties; or (viii) failure to comply with the lawful
    directions of the Board of Directors which are otherwise consistent with the terms of your employment under this letter agreement,
    which failure has continued for a period of at least 10 days after delivery by the Company to you of written demand by the Board
    of Directors. 
	 	 	 	 
	 	 	 	“Good
    Reason” means the occurrence of any of the following circumstances, without your express consent: you resign due to (i) a material
    reduction of your title or authority, (ii) a material reduction in your salary or benefits (other than a reduction that generally
    applies to the officers at your level in the Company or, as applicable, after a transaction in which the Company or substantially
    all its assets is acquired, in the successor entity at that time), (iii) any material breach of this Agreement by the Company which
    is not cured within 30 days after written notice by you; or (iv) a change of the principal non-temporary location in which you are
    required to perform your services to any location exceeding 35 miles from Carlsbad, California (it being understood that at
    present you will be working primarily from a remote location). In no event shall a resignation be considered to be with Good Reason
    unless the resignation occurs after but within 30 days after the initiation of the item of Good Reason. 
	 	 	 	 
	 	 	 	It
    is the intention of both the Company and you that the benefits and rights to which you could be entitled pursuant to this letter
    agreement comply with Section 409A of the Internal Revenue Code and the Treasury Regulations and other guidance promulgated or issued
    thereunder (“Section 409A”), to the extent that the requirements of Section 409A are applicable thereto; and the provisions
    of this letter agreement shall be construed in a manner consistent with that intention. Without limitation, if (and only to the extent)
    any amounts payable to you on account of separation from service are considered deferred compensation under Section 409A and/or not
    within any specified exception from Section 409A, and you are a “specified employee” at the time of separation from service,
    then no payment or benefit shall be made before the date that is six months after your separation from service. If you or the Company
    believes, at any time, that any such benefit or right that is subject to Section 409A does not so comply, it shall promptly advise
    the other and shall negotiate reasonably and in good faith to amend the terms of such benefits and rights such that they comply with
    Section 409A (with the most limited possible economic effect on you and on the Company).

 

    	 

    	 

    

 

	 	12.	Arbitration:	You
    and the Company agree to arbitrate before a neutral arbitrator (at JAMS, unless the parties otherwise agree) any and all claims or
    disputes arising out of this letter agreement and any and all claims arising from or relating to your employment with the Company,
    claims of wrongful termination, retaliation, discrimination, harassment, breach of contract, breach of the covenant of good faith
    and fair dealing, defamation, invasion of privacy, fraud, misrepresentation, constructive discharge or failure to provide a leave
    of absence, or claims regarding stock options or bonuses, commissions, infliction of emotional distress or unfair business practices.
	 	 	 	 
	 	 	 	The
    arbitrator’s decision must be written and must include the findings of fact and law that support the decision. The arbitrator’s
    decision will be final and binding on both parties, except to the extent applicable law allows for judicial review of arbitration
    awards. The arbitrator may award any remedies that would otherwise be available to the parties if they were to bring the dispute
    in court. The arbitration will be conducted in accordance with JAMS’ employment disputes arbitration rules. The arbitration
    will take place in San Diego, California and be governed by California procedural law. 
	 	 	 	 
	 	 	 	You
    and the Company will share the costs of arbitration equally, except that the Company will bear the cost of any administrative fee
    of the tribunal, the arbitrator’s fee and any other type of expense or cost that you would not be required to bear if you were
    to bring the dispute or claim in court. Both the Company and you will be responsible for their own attorneys’ fees, and the
    arbitrator may not award attorneys’ fees unless a statute or contract at issue specifically authorizes such an award.
	 	 	 	 
	 	 	 	The
    foregoing notwithstanding, this arbitration provision does not apply to (a) workers’ compensation or unemployment insurance
    claims, (b) stock appraisal rights under the Delaware General Corporation Law, (c) any other claims that an employer cannot,
    in accordance with applicable state law, require (either pursuant to an arbitration agreement or otherwise) an employee to arbitrate,
    or (d) claims concerning the ownership, validity, infringement, misappropriation, disclosure, misuse or enforceability of any confidential
    information, patent right, copyright, mask work, trademark or any other trade secret or intellectual property held or sought by either
    you or the Company (whether or not arising under the Confidential Information and Invention Assignment Agreement).
	 	 	 	 
	 	 	 	If
    an arbitrator or court of competent jurisdiction (the “Neutral”) determines that any provision of this arbitration
    provision is illegal or unenforceable, then the Neutral shall modify or replace the language of this arbitration provision with a
    valid and enforceable provision, but only to the minimum extent necessary to render this arbitration provision legal and enforceable.

 

    	 

    	 

    

 

Your
employment is “At Will”, meaning that either you or the Company may terminate your employment at any time for any reason
or no reason, without further contractual obligation or contractual liability (except as may be expressly set forth in Section 11 of
this letter agreement).

 

This
offer is subject to approval by the Board of Directors and its Compensation Committee as well as the successful completion of the Company’s
pre-employment background check. Prior to commencement of employment, you will be required to complete the Company’s Employment
Application, sign the Company’s standard form of Confidential Information and Invention Assignment Agreement, and complete a drug
screening test. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your
identity and eligibility for employment in the United States.

 

We
are excited about your future with our Company and the talents and background you add to our team. Please acknowledge your acceptance
of this offer by signing and returning a copy of this letter to me by Friday April 23, 2021.

 

We
look forward to working with you!

 

Sincerely,

 

	/s/
    Chris Lotz	 	 
	Chris
    Lotz	 	 
	Vice
    President	 	 
	Chief
    Financial Officer	 	 

 

Acceptance

 

Accepted
and agreed to this 22nd day of April, 2021.

 

	 	 	/s/
    Tariq Arshad
	 	 	Tariq
    Arshad, MDExhibit
10.2

 

June
22, 2021

 

VIA
FEDEX

 

A.G.P./Alliance
Global Partners

590
Madison Avenue

New
York, NY 10022

Attention:
Tom Higgins

 

Re:
Termination of Sales Agreement with Ritter Pharmaceuticals, Inc. (nka Qualigen Therapeutics, Inc.)

 

Gentlemen,

 

Pursuant
to Section 11(b) of the Sales Agreement dated November 6, 2019 between you and Ritter Pharmaceuticals, Inc. (now known as Qualigen Therapeutics,
Inc.), we hereby notify you that we are terminating such Sales Agreement. Allowing for the required advance-notice period, the effective
date of the termination will be July 3, 2021. It would be convenient and much appreciated if we could agree that the date of termination
could be accelerated to June 25; please email if this is acceptable.

 

	 	Very
    truly yours,
	 	 
	 	/s/
    Michael S. Poirier
	 	Michael
    S. Poirier
	 	Chairman,
    Chief Executive Officer and President, 
	 	Qualigen
    Therapeutics, Inc.

 

	cc
    (via FedEx):	Mintz,
    Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	 	666
    Third Avenue
	 	New
    York, New York 10017
	 	Attention:
    Anthony J. Marsico, Esq.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]